Literature DB >> 11384521

Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997.

Y J Hutin1, R J Williams, P Malfait, R Pebody, V N Loparev, S L Ropp, M Rodriguez, J C Knight, F K Tshioko, A S Khan, M V Szczeniowski, J J Esposito.   

Abstract

Human monkeypox is a zoonotic smallpox-like disease caused by an orthopoxvirus of interhuman transmissibility too low to sustain spread in susceptible populations. In February 1997, 88 cases of febrile pustular rash were identified for the previous 12 months in 12 villages of the Katako-Kombe Health Zone, Democratic Republic of Congo (attack rate = 22 per 1,000; case-fatality rate = 3.7%). Seven were active cases confirmed by virus isolation. Orthopoxvirus- neutralizing antibodies were detected in 54% of 72 patients who provided serum and 25% of 59 wild-caught animals, mainly squirrels. Hemagglutination-inhibition assays and Western blotting detected antibodies in 68% and 73% of patients, respectively. Vaccinia vaccination, which protects against monkeypox, ceased by 1983 after global smallpox eradication, leading to an increase in the proportion of susceptible people.

Entities:  

Mesh:

Year:  2001        PMID: 11384521      PMCID: PMC2631782          DOI: 10.3201/eid0703.010311

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  17 in total

1.  The role of squirrels in sustaining monkeypox virus transmission.

Authors:  L Khodakevich; M Szczeniowski; Z Jezek; S Marennikova; J Nakano; D Messinger
Journal:  Trop Geogr Med       Date:  1987-04

2.  Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Primary percutaneous vaccination.

Authors:  J D Cherry; K McIntosh; J D Connor; A S Benenson; D W Alling; U T Rolfe; W A Todd; J E Schanberger
Journal:  J Infect Dis       Date:  1977-01       Impact factor: 5.226

3.  Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Standard percutaneous revaccination of children who receive primary percutaneous vaccination.

Authors:  K McIntosh; J D Cherry; A S Benenson; J D Connor; D W Alling; U T Rolfe; W A Todd; J E Schanberger; M J Mattheis
Journal:  J Infect Dis       Date:  1977-01       Impact factor: 5.226

4.  Human monkeypox: confusion with chickenpox.

Authors:  Z Jezek; M Szczeniowski; K M Paluku; M Mutombo; B Grab
Journal:  Acta Trop       Date:  1988-12       Impact factor: 3.112

5.  Four generations of probable person-to-person transmission of human monkeypox.

Authors:  Z Jezek; I Arita; M Mutombo; C Dunn; J H Nakano; M Szczeniowski
Journal:  Am J Epidemiol       Date:  1986-06       Impact factor: 4.897

6.  Human monkeypox: secondary attack rates.

Authors:  Z Jezek; B Grab; M V Szczeniowski; K M Paluku; M Mutombo
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

7.  The transmission potential of monkeypox virus in human populations.

Authors:  P E Fine; Z Jezek; B Grab; H Dixon
Journal:  Int J Epidemiol       Date:  1988-09       Impact factor: 7.196

8.  Monkeypox virus: ecology and public health significance.

Authors:  L Khodakevich; Z Jezek; D Messinger
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

9.  Human monkeypox: a newly emerged orthopoxvirus zoonosis in the tropical rain forests of Africa.

Authors:  I Arita; Z Jezek; L Khodakevich; K Ruti
Journal:  Am J Trop Med Hyg       Date:  1985-07       Impact factor: 2.345

10.  Orthopoxvirus DNA: a comparison of restriction profiles and maps.

Authors:  J J Esposito; J C Knight
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

View more
  119 in total

1.  Detection of smallpox virus DNA by LightCycler PCR.

Authors:  Mark J Espy; Franklin R Cockerill III; Richard F Meyer; Michael D Bowen; Gregory A Poland; Ted L Hadfield; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome.

Authors:  Chris Upton; Stephanie Slack; Arwen L Hunter; Angelika Ehlers; Rachel L Roper
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

3.  Monkeypox outbreak among pet owners.

Authors:  James Maskalyk
Journal:  CMAJ       Date:  2003-07-08       Impact factor: 8.262

4.  Smallpox: an ancient disease enters the modern era of virogenomics.

Authors:  Grant McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-12       Impact factor: 11.205

5.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

6.  Systematic Review of Important Viral Diseases in Africa in Light of the 'One Health' Concept.

Authors:  Ravendra P Chauhan; Zelalem G Dessie; Ayman Noreddin; Mohamed E El Zowalaty
Journal:  Pathogens       Date:  2020-04-20

7.  Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection.

Authors:  Ryan D Estep; Ilhem Messaoudi; Megan A O'Connor; Helen Li; Jerald Sprague; Alexander Barron; Flora Engelmann; Bonnie Yen; Michael F Powers; John M Jones; Bridget A Robinson; Beata U Orzechowska; Minsha Manoharan; Alfred Legasse; Shannon Planer; Jennifer Wilk; Michael K Axthelm; Scott W Wong
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

8.  Smallpox 2003.

Authors:  Lindsay Nicolle
Journal:  Can J Infect Dis       Date:  2003-09

9.  Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection.

Authors:  Kevin L Karem; Mary Reynolds; Christine Hughes; Zach Braden; Pragati Nigam; Shane Crotty; John Glidewell; Rafi Ahmed; Rama Amara; Inger K Damon
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

10.  Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.

Authors:  J W Hooper; E Thompson; C Wilhelmsen; M Zimmerman; M Ait Ichou; S E Steffen; C S Schmaljohn; A L Schmaljohn; P B Jahrling
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.